Full video transcriptClick to expand
Auto-generated transcript of @jimmyacusensei's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Low libido this is for you women. Don't worry. I didn't forget about you
- 0:05So for women who are in their older 50s 60s that you may have low libido
- 0:10I got three ways for you also to help you increase your libido, right? So point number one
- 0:16You're gonna take your foot right between the first and your big toe and your second toe in between right here
- 0:23Okay, you're gonna push it's gonna be super sensitive
- 0:26You're gonna do it for about 30 seconds all right every day once a day for 30 seconds
- 0:30Then you're gonna go to your ankle you see this bone right here draw a line right here pinch between your Achilles tendon
- 0:37You're gonna pinch right there for 30 seconds to and the third point right along your heel
- 0:42Just draw a line down here draw a line down here
- 0:44You're gonna massage right there for 30 seconds to do this at least twice a day right before you go to bed
- 0:51Get the juices flowing guide blood to your uterus and your ovaries increase that libido
TRT on TikTok: separating the hype from the hormone data
Quick answer
Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone. The creator targets a real and underserved population but bypasses evidence-based options including low-dose testosterone therapy, which has robust RCT support for improving sexual desire in postmenopausal women. Acupressure at the specific points described has limited low-certainty evidence for subjective sexual function improvement, but has not been shown to alter uterine or ovarian blood flow as claimed.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT on TikTok: separating the hype from the hormone data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TRT on TikTok: separating the hype from the hormone data should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "TRT on TikTok: separating the hype from the hormone data" from jimmyacusensei. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone.
The reason this review is not generic is the source wording and the canonical claim label "trt tiktok 7200392108832771370." In this clip, the useful excerpt is: "Low libido this is for you women." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone. The creator targets a real and underserved population but bypasses evidence-based options including low-dose testosterone therapy, which has robust RCT support for improving sexual desire in postmenopausal women. Acupressure at the specific points described has limited low-certainty evidence for subjective sexual function improvement, but has not been shown to alter uterine or ovarian blood flow as claimed.
- Hypoactive sexual desire disorder (HSDD) affects an estimated 10-40% of postmenopausal women and has identifiable hormonal causes that respond to evidence-based treatments.
- A 2019 Global Consensus Position Statement in the Journal of Clinical Endocrinology and Metabolism found low-dose testosterone therapy has the strongest RCT evidence for improving sexual desire in postmenopausal women.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Hypoactive sexual desire disorder (HSDD) affects an estimated 10-40% of postmenopausal women and has identifiable hormonal causes that respond to evidence-based treatments.
- A 2019 Global Consensus Position Statement in the Journal of Clinical Endocrinology and Metabolism found low-dose testosterone therapy has the strongest RCT evidence for improving sexual desire in postmenopausal women.
- Salehi et al. (2019) found acupressure at Spleen 6 improved sexual function scores versus sham in a 60-person RCT, but the study was small and outcomes were self-reported.
- A 2021 systematic review in Menopause (Ee et al.) rated evidence for acupressure and menopause symptoms as low certainty, with sexual function as a secondary outcome.
- There is no published vascular physiology evidence that foot acupressure redirects blood flow to the uterus or ovaries as the creator claims.
- Acupressure at the described points carries essentially no harm risk and may provide subjective benefit, but it should not substitute for clinical evaluation of hormonal status.
- Women in their 50s and 60s with persistent low libido that affects quality of life should seek evaluation of estrogen, testosterone, and thyroid levels before assuming lifestyle measures are sufficient.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @jimmyacusensei actually say?
The creator claimed that pressing three specific foot points, between the first and second toes, near the Achilles tendon at the ankle, and along the heel, for 30 seconds each, twice daily, will "guide blood to your uterus and your ovaries" and "increase that libido" in women in their 50s and 60s. No qualifications, no caveats, no mention of what actually drives low libido at that life stage.
To be fair, the creator is pointing to areas that loosely correspond to classical acupressure points. The first web space of the foot is near Liver 3 (Taichong) in traditional Chinese medicine. The medial ankle region corresponds to Kidney 3 and Spleen 6, points historically used in TCM for reproductive complaints. So this isn't random button-mashing. It's a real tradition. The question is whether that tradition holds up when you put it in front of a randomized controlled trial.
Does the science back this up?
The honest answer is: weakly, and not specifically for libido. There is some low-quality evidence that acupressure and acupuncture may improve self-reported sexual function in perimenopausal and postmenopausal women, but the effect sizes are modest and the studies are riddled with methodological problems.
A 2021 systematic review by Ee et al. in Menopause looked at acupuncture and acupressure for menopause symptoms and found limited, low-certainty evidence for improvements in quality of life and some vasomotor symptoms. Sexual function was a secondary outcome at best. A 2019 study by Salehi et al. in Complementary Therapies in Clinical Practice found acupressure at Spleen 6 improved sexual function scores in postmenopausal women compared to sham, but the sample was small (n=60) and the outcome measure was self-reported. That is not nothing, but it is a long way from a confident clinical recommendation.
The claim that pressing your foot will literally "guide blood to your uterus" is not supported by vascular physiology. Uterine and ovarian blood flow is regulated by hormones, autonomic tone, and local vasodilatory signals, not reflexology maps.
What did they get wrong (or right)?
What they got wrong, and it matters: the creator skips entirely over why libido declines in women in their 50s and 60s. The dominant drivers are estrogen decline, testosterone decline (yes, women have testosterone too), genitourinary syndrome of menopause, sleep disruption, mood disorders, and relationship factors. A 2019 review by Islam et al. in Sexual Medicine Reviews laid this out clearly. None of those causes respond to foot massage.
The "get the juices flowing" framing is also a problem. It implies a hydraulic model of arousal that oversimplifies female sexual response considerably. It also sidesteps the fact that for many women in this age group, low libido is a symptom with identifiable hormonal causes that respond to evidence-based treatments.
What they got partially right: the specific points named are at least consistent with TCM tradition rather than invented. And recommending a low-risk daily self-care practice is not dangerous. It just should not be presented as a standalone solution for a condition with real clinical underpinnings.
What should you actually know?
Low libido in postmenopausal women is a legitimate medical concern with a clinical name: hypoactive sexual desire disorder (HSDD). The FDA has approved treatments for it. Flibanserin is approved for premenopausal women. For postmenopausal women, off-label low-dose testosterone therapy has the strongest evidence base for improving sexual desire, supported by multiple RCTs including the large Intrinsa trials and summarized in the 2019 Global Consensus Position Statement on testosterone use in women published in The Journal of Clinical Endocrinology and Metabolism.
Acupressure as an adjunct, meaning alongside real evaluation and treatment, is unlikely to cause harm and may provide some subjective benefit. As a replacement for addressing hormonal deficiency, it falls short. If you are a woman in your 50s or 60s dealing with low libido and it is affecting your quality of life, that is worth a conversation with a clinician who can actually assess your hormone levels and rule out treatable causes.
Pressing your heel for 30 seconds is not a clinical intervention. It is not wrong to try. It is wrong to stop there.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
jimmyacusensei · TikTok creator
249.9K views on this video
TRT on TikTok: separating the hype from the hormone data
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about hypoactive sexual desire disorder (hsdd) affects an estimated 10-40% of?
Hypoactive sexual desire disorder (HSDD) affects an estimated 10-40% of postmenopausal women and has identifiable hormonal causes that respond to evidence-based treatments.
What does the video say about a 2019 global consensus position statement in the journal of?
A 2019 Global Consensus Position Statement in the Journal of Clinical Endocrinology and Metabolism found low-dose testosterone therapy has the strongest RCT evidence for improving sexual desire in postmenopausal women.
What does the video say about salehi et al. (2019) found acupressure at spleen 6 improved?
Salehi et al. (2019) found acupressure at Spleen 6 improved sexual function scores versus sham in a 60-person RCT, but the study was small and outcomes were self-reported.
What does the video say about a 2021 systematic review in menopause (ee et al.) rated?
A 2021 systematic review in Menopause (Ee et al.) rated evidence for acupressure and menopause symptoms as low certainty, with sexual function as a secondary outcome.
What does the video say about there?
There is no published vascular physiology evidence that foot acupressure redirects blood flow to the uterus or ovaries as the creator claims.
What does the video say about acupressure at the described points carries essentially no harm risk?
Acupressure at the described points carries essentially no harm risk and may provide subjective benefit, but it should not substitute for clinical evaluation of hormonal status.
Not medical advice. This video was made by jimmyacusensei, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.